312 related articles for article (PubMed ID: 30442716)
41. Idiopathic Pulmonary Fibrosis: A Case Discussion.
Felton MK; Bautista B; Morrow LE; Malesker M
Consult Pharm; 2017 Jul; 32(7):406-411. PubMed ID: 28701252
[TBL] [Abstract][Full Text] [Related]
42. Nintedanib vs pirfenidone in the management of COVID-19 lung fibrosis: A single-centre study.
Singh P; Behera D; Gupta S; Deep A; Priyadarshini S; Padhan P
J R Coll Physicians Edinb; 2022 Jun; 52(2):100-104. PubMed ID: 36146989
[TBL] [Abstract][Full Text] [Related]
43. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Crestani B; Huggins JT; Kaye M; Costabel U; Glaspole I; Ogura T; Song JW; Stansen W; Quaresma M; Stowasser S; Kreuter M
Lancet Respir Med; 2019 Jan; 7(1):60-68. PubMed ID: 30224318
[TBL] [Abstract][Full Text] [Related]
44. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
45. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
[TBL] [Abstract][Full Text] [Related]
46. Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis.
Porse S; Hoyer N; Shaker SB
Respir Med; 2022; 204():107015. PubMed ID: 36347111
[TBL] [Abstract][Full Text] [Related]
47. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
Knüppel L; Ishikawa Y; Aichler M; Heinzelmann K; Hatz R; Behr J; Walch A; Bächinger HP; Eickelberg O; Staab-Weijnitz CA
Am J Respir Cell Mol Biol; 2017 Jul; 57(1):77-90. PubMed ID: 28257580
[TBL] [Abstract][Full Text] [Related]
48. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Barratt SL; Mulholland S; Al Jbour K; Steer H; Gutsche M; Foley N; Srivastava R; Sharp C; Adamali HI
Front Pharmacol; 2018; 9():1480. PubMed ID: 30618768
[No Abstract] [Full Text] [Related]
49. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
Wongkarnjana A; Yanagihara T; Kolb MR
Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
[No Abstract] [Full Text] [Related]
50. Health economic evaluation in idiopathic pulmonary fibrosis in France.
Porte F; Cottin V; Catella L; Luciani L; Le Lay K; Bénard S
Curr Med Res Opin; 2018 Oct; 34(10):1731-1740. PubMed ID: 29368948
[TBL] [Abstract][Full Text] [Related]
51. Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE.
Kolonics-Farkas AM; Šterclová M; Mogulkoc N; Kus J; Hájková M; Müller V; Jovanovic D; Tekavec-Trkanjec J; Littnerová S; Hejduk K; Vašáková M
Drug Saf; 2020 Oct; 43(10):971-980. PubMed ID: 32734423
[TBL] [Abstract][Full Text] [Related]
52. Glasgow prognostic score and body mass index predict short-term discontinuation of the antifibrotic agents pirfenidone and nintedanib.
Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Tsurumaki H; Shin Y; Wakamatsu I; Kasahara N; Yamaguchi K; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
Respir Investig; 2024 May; 62(3):388-394. PubMed ID: 38460356
[TBL] [Abstract][Full Text] [Related]
53. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S
Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750
[TBL] [Abstract][Full Text] [Related]
54. Management of Idiopathic Pulmonary Fibrosis.
Pleasants R; Tighe RM
Ann Pharmacother; 2019 Dec; 53(12):1238-1248. PubMed ID: 31280590
[No Abstract] [Full Text] [Related]
55. Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects.
Luedtke D; Marzin K; Jungnik A; von Wangenheim U; Dallinger C
Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):533-541. PubMed ID: 29500603
[TBL] [Abstract][Full Text] [Related]
56. Disease stage-related survival in idiopathic pulmonary fibrosis patients treated with nintedanib and pirfenidone: An exploratory study.
Bocchino M; Bruzzese D; Scioscia G; Capitelli L; Tondo P; Rea G; Barbaro MPF; Lacedonia D
Respir Med Res; 2023 Nov; 84():101013. PubMed ID: 37302161
[TBL] [Abstract][Full Text] [Related]
57. Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis.
King CS; Nathan SD
Curr Opin Pulm Med; 2015 Sep; 21(5):479-89. PubMed ID: 26164298
[TBL] [Abstract][Full Text] [Related]
58. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
59. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).
Costabel U; Albera C; Lancaster LH; Lin CY; Hormel P; Hulter HN; Noble PW
Respiration; 2017; 94(5):408-415. PubMed ID: 28898890
[TBL] [Abstract][Full Text] [Related]
60. [Idiopathic Pulmonary Fibrosis].
Prasse A
Pneumologie; 2015 Oct; 69(10):608-14; quiz 615. PubMed ID: 26444136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
